Prostate cancer screening: The controversy continues

BMJ (Online)

Volumn 339, Issue 7724, 2009, Pages 784-786

  Stark, Jennifer R ^a   Mucci, Lorelei ^a,b,c   Rothman, Kenneth J ^d,e   Adami, Hans Olov ^b,c,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIBODY LABELING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; DIAGNOSTIC ERROR; DIGITAL RECTAL EXAMINATION; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MALE; MEDICAL ERROR; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY;

EID: 70349646720     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. American Urological Association. Early detection of prostate cancer. AUA, 2009.
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328
4. Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer 2008;113:1315-1323
5. Federman DG, Goyal S, Kamina A, Peduzzi P, Concato J. Informed consent for PSA screening: does it happen? Eff Clin Pract 1999;2:152-157
6. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007;167:2497-2502
7. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-1887 (Pubitemid 351767195)
8. Lamplugh M, Gilmore P, Quinlan T, Cornford P. PSA testing: are patients aware of what lies ahead? Ann R Coll Surg Engl 2006;88:284-288
9. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
10. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719 (Pubitemid 38725420)
11. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101 (Pubitemid 40617061)
12. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-443
13. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008;9:445-452
14. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-1154
15. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National hospital discharge survey. National Health Statistics Reports: Washington, DC: US Department of Health and Human Services, 2008.
16. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008;101:547-555
17. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-448 (Pubitemid 351665443)
18. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294
19. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
20. Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009;100:1198-1204
21. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001;19:3490-3499 (Pubitemid 32730086)
22. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-383